Dendritic Cell Therapies and Modulation of Endogenous DC to Overcome I-O Resistance of "Cold" Tumors

Explore advanced immunotherapy strategies for overcoming resistance in "cold" tumors through dendritic cell therapies and endogenous DC modulation in this 48-minute webinar. Learn about type-1-polarized dendritic cells (DC1) matured under acute viral infection conditions that selectively activate type-1 immunity and promote cytotoxic T cell infiltration while excluding regulatory T cells. Discover how polarized DC1s enhance cross-presentation of tumor-associated antigens and induce DNAM1- and NKG2D-expressing CTLs that amplify weak TCR signals for improved cancer cell recognition. Examine the chemokine-modulatory regimen (CKM) combining TLR3-ligand and interferon that selectively targets cancer lesions while sparing healthy tissues, enabling systemic application for uniform CTL infiltration of multiple cold tumors. Review clinical trial results including NCT03403634 testing systemic interferon-α2b and rintatolimod in metastatic triple-negative breast cancer patients, showing excellent tolerability and 10.3-fold increases in intratumoral CTL markers. Analyze outcomes from neoadjuvant and intraperitoneal CKM studies in breast and ovarian cancers, with 7 of 9 patients achieving pathologic complete responses or microscopic disease. Understand the molecular mechanisms involving interferons, TLR-ligands, CTL/NK-attracting chemokines, and their interplay with suppressive mediators in tumor microenvironments. Preview upcoming trials combining CKM and DC therapies with immune checkpoint inhibitors and adoptive T cell therapies for enhanced immunotherapeutic efficacy.